Quest Diagnostics (DGX)
(Delayed Data from NYSE)
$153.98 USD
+0.99 (0.65%)
Updated Sep 23, 2024 04:00 PM ET
After-Market: $153.96 -0.02 (-0.01%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth B Momentum B VGM
Company Summary
Headquartered in Secaucus, New Jersey, Quest Diagnostics Inc. provides a broad range of diagnostic information services to patients, clinicians and healthcare organizations. The company provide services to Independent Delivery Networks (IDN) throughout the United States, through its Professional Lab Services (PLS) offerings, which allow them to build and execute their laboratory strategy, improve quality, reduce healthcare costs and focus on core competencies. The company is a key provider of reference testing for approximately half of the hospitals in the United States.
It also offers physician services that are reimbursed by Medicare ...
Company Summary
Headquartered in Secaucus, New Jersey, Quest Diagnostics Inc. provides a broad range of diagnostic information services to patients, clinicians and healthcare organizations. The company provide services to Independent Delivery Networks (IDN) throughout the United States, through its Professional Lab Services (PLS) offerings, which allow them to build and execute their laboratory strategy, improve quality, reduce healthcare costs and focus on core competencies. The company is a key provider of reference testing for approximately half of the hospitals in the United States.
It also offers physician services that are reimbursed by Medicare under a physician fee schedule, subject to adjustment on an annual basis. Further, the company is growing its array of Advanced Diagnostics offerings, which target faster growth through an innovation testing model. Advanced Diagnostics also encompasses other key areas, such as molecular genomics, oncology, neurology, women's reproductive health and cardiometabolic health.
The company has grown mainly through strategic acquisitions and aims to drive operational excellence across the customer value chain and operations. The multi-year Invigorate initiative was introduced in 2022 in this regard. It consists of several flagship programs to reduce the cost structure and improve performance.
Quest Diagnostics operates through two units: Diagnostic Information Services (DIS) and Diagnostic Solutions (DS).
The DIS segment (97% of net revenues in 2023) provides routine, non-routine and advanced clinical testing, anatomic pathology testing and other diagnostic information services. The DS segment (3% of net revenues in 2023) comprises the risk assessment services business and healthcare information technology business.
In addition, Quest Diagnostics is the first to offer online patient appointment scheduling and a patient connectivity solution through the MyQuest patient healthcare portal. The company also publishes Quest Diagnostics Health Trends reports — a series of data-supported scientific reports that provide insights into critical healthcare issues.
General Information
Quest Diagnostics Incorporated
500 PLAZA DRIVE
SECAUCUS, NJ 07094
Phone: 973-520-2700
Fax: 201-462-4169
Web: http://www.questdiagnostics.com
Email: investor@questdiagnostics.com
Industry | Medical - Outpatient and Home Healthcare |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 6/30/2024 |
Earnings Date | 10/22/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | 2.27 |
Current Year EPS Consensus Estimate | 8.89 |
Estimated Long-Term EPS Growth Rate | 6.20 |
Earnings Date | 10/22/2024 |
Price and Volume Information
Zacks Rank | |
Yesterday's Close | 152.99 |
52 Week High | 159.36 |
52 Week Low | 119.59 |
Beta | 0.89 |
20 Day Moving Average | 668,908.06 |
Target Price Consensus | 155.07 |
4 Week | -0.37 |
12 Week | 11.77 |
YTD | 10.96 |
4 Week | -1.56 |
12 Week | 7.02 |
YTD | -7.19 |
Shares Outstanding (millions) | 111.32 |
Market Capitalization (millions) | 17,030.42 |
Short Ratio | NA |
Last Split Date | 6/21/2005 |
Dividend Yield | 1.96% |
Annual Dividend | $3.00 |
Payout Ratio | 0.34 |
Change in Payout Ratio | 0.07 |
Last Dividend Payout / Amount | 7/8/2024 / $0.75 |
Fundamental Ratios
P/E (F1) | 17.21 |
Trailing 12 Months | 17.47 |
PEG Ratio | 2.79 |
vs. Previous Year | 2.17% |
vs. Previous Quarter | 15.20% |
vs. Previous Year | 2.52% |
vs. Previous Quarter | 1.31% |
Price/Book | 2.56 |
Price/Cash Flow | 12.00 |
Price / Sales | 1.82 |
6/30/24 | 15.35 |
3/31/24 | 15.52 |
12/31/23 | 15.79 |
6/30/24 | 7.19 |
3/31/24 | 7.23 |
12/31/23 | 7.40 |
6/30/24 | 1.00 |
3/31/24 | 0.97 |
12/31/23 | 1.31 |
6/30/24 | 0.91 |
3/31/24 | 0.89 |
12/31/23 | 1.20 |
6/30/24 | 10.65 |
3/31/24 | 10.68 |
12/31/23 | 10.74 |
6/30/24 | 8.99 |
3/31/24 | 9.11 |
12/31/23 | 9.23 |
6/30/24 | 11.94 |
3/31/24 | 12.05 |
12/31/23 | 12.21 |
6/30/24 | 59.79 |
3/31/24 | 58.23 |
12/31/23 | 56.41 |
6/30/24 | 34.09 |
3/31/24 | 33.74 |
12/31/23 | 33.15 |
6/30/24 | 0.57 |
3/31/24 | 0.59 |
12/31/23 | 0.70 |
6/30/24 | 36.92 |
3/31/24 | 37.50 |
12/31/23 | 41.43 |